Literature DB >> 2721009

Squamous cell carcinoma of the oral cavity: a retrospective analysis of treatment and prognosis.

J Wildt1, P Bjerrum, O Elbrønd.   

Abstract

A retrospective study of 267 patients with an oral cavity squamous cell carcinoma is presented. It includes all patients from a geographically well-defined area during an 11 and one-quarter year period. Thirty-five percent of the patients were treated with radical surgery, 40% with curative-dosage radiotherapy and 22% with combined therapy. One-year survival with No Evidence of Disease (NED) was 48%. Almost all recurrences were within the first year following completion of the initial treatment. Treatment results were especially ineffective in large local tumour cases (T3 and T4) and in instances with extensive regional lymph node metastases (N2 and N3). The observed 5-year survival ('crude survival') was 44%. All parameters for the course of disease following diagnosis and treatment were significantly correlated to disease stage.

Entities:  

Mesh:

Year:  1989        PMID: 2721009     DOI: 10.1111/j.1365-2273.1989.tb00345.x

Source DB:  PubMed          Journal:  Clin Otolaryngol Allied Sci        ISSN: 0307-7772


  3 in total

1.  [Quality of life of patients with squamous cell carcinoma of the oral cavity].

Authors:  J Rabbels; M Wyzisk; M Siessegger; B Klesper; T Reuther; A C Kübler
Journal:  Mund Kiefer Gesichtschir       Date:  2005-09

2.  Photodynamic therapy of early stage oral cavity and oropharynx neoplasms: an outcome analysis of 170 patients.

Authors:  Baris Karakullukcu; Kim van Oudenaarde; Marcel P Copper; W M C Klop; Robert van Veen; Maarten Wildeman; I Bing Tan
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-08-13       Impact factor: 2.503

3.  Immunohistochemical study of CD44s expression in oral squamous cell carcinoma-its correlation with prognostic parameters.

Authors:  Kn Hema; Kavita Rao; Hs Uma Devi; Ns Priya; T Smitha; Hs Sheethal
Journal:  J Oral Maxillofac Pathol       Date:  2014-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.